General Commentary
Published on 28 Nov 2022
Commentary: A GSH/CB dual-controlled self-assembled nanomedicine for high-efficacy doxorubicin-resistant breast cancer therapy
in Experimental Pharmacology and Drug Discovery
- 904 views
General Commentary
Published on 28 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 28 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 28 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 24 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 24 Nov 2022
in Experimental Pharmacology and Drug Discovery
Methods
Published on 24 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 23 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 22 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 21 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Review
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Editorial
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery
Original Research
Published on 18 Nov 2022
in Experimental Pharmacology and Drug Discovery